ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.
SUPN's revenue has rebounded from $149.8M in 2025Q1 to $356.0M in 2026Q3 on a consistently high gross margin of 84.6% to 90.1%, suggesting a durable high-margin product mix.
Price trend, volume and key moving averages
Trailing total returns as of 11/17/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $1.32+24.5% vs $1.06 | $356M+8.1% vs $329M |
Q3 2026 Aug 3, 2026 | $1.15+32.3% vs $0.87 | $343M+12.0% vs $306M |
Q2 2026 Apr 30, 2026 | $0.96+50.0% vs $0.64 | $317M+16.2% vs $273M |
Q1 2026 Feb 26, 2026 | $0.82+26.2% vs $0.65 | $358M+17.1% vs $306M |
ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Valuation and Earnings This table compares Chugai Pharmaceutical

Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades landing on names that have struggled all year.
Benchmark SUPN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Supernus Pharmaceuticals, Inc. (SUPN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $28.83 | $3.52B | 7.82 | 4.29% | 32.75% | — | — | |
| $36.48 | $1.43B | 39.48 | 3.63% | 5.08% | 5.53% | — | |
| $18.67 | $3.2B | 9.04 | 11.87% | 30.13% | 28.03% | — | |
| $18.49 | $1.36B | 6.89 | 18.52% | 43.79% | 15.84% | — | |
| $16.18 | $2.24B | -1.27 | -2.75% | -43.27% | -68.13% | 7.11% | |
| $101.72 | $6.62B | 25.78 | 0.5% | 17.28% | 21.72% | — |
Supernus Pharmaceuticals, Inc. (SUPN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Supernus Pharmaceuticals, Inc. (SUPN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Nov 2, 2026·SEC
Oct 29, 2026·SEC
Get notified when SUPN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Supernus Pharmaceuticals, Inc. (SUPN) stock FAQ — growth, dividends, profitability & financials explained
Supernus Pharmaceuticals, Inc. (SUPN) reported $1.37B in revenue over the trailing twelve months. Revenue was $1.24B in fiscal year 2025. That is 13839% more than the $8.9M of fiscal year 2008.
Supernus Pharmaceuticals, Inc. (SUPN) grew revenue by 16.3% over the trailing twelve months, compared with the twelve months before.
Yes. Supernus Pharmaceuticals, Inc. (SUPN) earned $450.0M in net income over the trailing twelve months (a 32.8% net margin).
Supernus Pharmaceuticals, Inc. (SUPN) generated $31.0M in free cash flow over the trailing twelve months.